We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.

Filter by:

NEWS

June 14, 2019
Information regarding our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital
Since we get several questions about our ongoing Amyotrophic Lateral Sclerosis (ALS) study at Sahlgrenska University Hospital, we want to provide the following information on behalf of the company: 1. The study is fully recruited and ongoing 2. We plan to report the study’s outcome as soon as the study is completed and analysis of…
Read More
March 4, 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of TFS to perform CRO services for TIKOMED’s Phase 2 study in clinical islet transplantation. The study is planned to be performed as an international multi-center study. IBsolvMIR is TIKOMED’s immune modulating drug candidate currently in Phase 2…
Read More
February 8, 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its successful completion of the company’s latest fundraising of 8 Million Euros to support the ongoing clinical development program for both the ILB-program and the IBsolvMIR® program. TIKOMED is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB…
Read More
February 6, 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced the appointment of Shadow lake Group (SLG) to represent TikoMed as strategic advisor and business development representative for the licensing process of IBsolvMIR® in Canada. IBsolvMIR is TikoMed’s immune modulating drug candidate currently in Phase 2 development. IBsolvMir addresses the…
Read More
November 30, 2018
TIKOMED Granted Permission for Phase 2 Clinical Trial in Islet Cell Transplantation by the Swedish Medical Product Agency
VIKEN, Sweden, November 19, 2018 (Newswire) -TIKOMED, a specialty pharmaceutical company developing IBsolvMIR, an infusion product for improving outcome in cell transplantation announced today that it was granted approval for a clinical trial (Phase 2) in Islet Cell Transplantation to be performed in collaboration with Karolinska University Hospital and Uppsala University Hospital by the Swedish…
Read More
November 2, 2018
First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden.</p> <p>Anders Svenson…
Read More
August 20, 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, has been granted permission by the UK Medicines and Healthcare products Regulatory Agency, for a phase II clinical trial of the company’s investigational drug ILB for patients with Amyotrophic Lateral Sclerosis (ALS),…
Read More
August 14, 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company today has started its clinical trial (Phase 2a) in Amyotrophic Lateral Sclerosis (ALS ) at Sahlgrenska University Hospital. Anders Svenson M.D., Chief Medical Officer…
Read More
July 5, 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company has been granted permission for a clinical trial (Phase 2a) in ALS (Amyotrophic Lateral Sclerosis) at Sahlgrenska University Hospital by the Swedish Medical Product Agency and…
Read More
ILB – A game changer in Glaucoma
TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, today announces that an abstract supporting the ongoing development of its proprietary technology ILB was presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held 29 – May 3…
Read More
June 5, 2018
Anders Kristensson appointed CEO of TikoMed
TikoMed, a privately-held biopharmaceutical company today announced the appointment of Anders Kristensson as their new Chief Executive Officer. He succeeds Adam Bruce founder and acting CEO, who will continue as Executive board member, building the IBsolvMIR® program. TikoMed is developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases (ILB program) and an infusion…
Read More

EVENTS

June 3, 2019
BIO International
TikoMed will be attending BIO. Anders Kristensson, CEO and Adam Bruce, Founder and Executive Board Member will be attending the meeting with a focus on finding partners and collaborations for our two programs ILB and IBsolvMIR. https://convention.bio.org/ The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of…
Read More
May 4, 2019
2019 ANNUAL MEETING TIKOMED AB
Kallelse till årsstämma i TIKOMED AB Aktieägarna i TIKOMED AB (org.nr. 556622-8960) kallas härmed till årsstämma den 17 juni 2019, kl. 11.00 på Restaurang Bryggan, Småbåtshamnen 16B i Höganäs. Aktieägare som önskar delta i bolagsstämman ombeds att senast kl.12.00 den 7 juni 2019 anmäla sin avsikt att delta till bolaget. Tillgängliga handlingar Årsredovisning och revisionsberättelse…
Read More
April 23, 2019
Cell and Gene on the Med
TikoMed will be pariticpating at The Cell & Gene Meeting on the Mediterranean, a two-day conference bringing together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program will feature expert-led panels, extensive…
Read More
January 5, 2019
TIKOMED WILL BE SENDING TEAM TO EAST/WEST CEO MEETING & BIOTECH SHOWCASE
The investor and networking conference for public and private biotech companies to meet with and present to investors and pharmaceutical executives during the course of the healthcare industry’s most important week of the year.…
Read More
November 4, 2018
TIKOMED WILL BE SENDING TEAM TO BIO-EUROPE
BIO-EUROPE attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts who come together for one week of intensive networking to discover new opportunities and promising partnerships. TikoMed will be sending representatives to take the opportunity to…
Read More
October 4, 2018
TIKOMED WILL SPEAK AT BIOTECH IN EUROPE FORUM
The 18th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Our CEO,…
Read More
October 3, 2018
Cell and Gene Meeting on the Mesa
TikoMed is kicking of partnering for its cell therapy program IBsolvMIR, founded in the finding of an effective treatment against IBMIR (Instant Blood Mediated Inflammatory Reaction), an activation of the innate immunity including complement avtivation, infiltration of inflammatory cells and clotting, TikoMed has performed extensive development and documented significant additional effects making IBsolvMIR the ideal…
Read More
August 29, 2018
LSX Nordic Congress 29-30 August, NASDAQ OFFICE, STOCKHOLM
TikoMed is pleased to announce that our Executive Board Member for IBsolvMIR, Adam Bruce, will be moderating two of the panels at the Biotech and Money meeting, LSX Nordic Congress at the NASDAQ office in Stockholm. Adam Bruce: I am very happy to have the opportunity to lead the two panels with such excellent panelists.…
Read More

SUBSCRIBE